3.2 5.b - Pharmaceutical power and disease eradication

GSK and pharmaceutical innovation

A pharmaceutical transnational corporation operates across national boundaries through research, manufacturing, licensing and sales networks. GSK is a named case: its decisions and partnerships can affect disease prevention far beyond the countries hosting its laboratories. Developing a product involves discovering or designing an intervention, evaluating it, gaining regulatory approval and organising consistent production. A scientific breakthrough becomes a public health benefit only when services can deliver it to people at risk.

GSK led the development of the RTS,S malaria vaccine over several decades, working with PATH and African research centres. The WHO implementation programme account published in March 2020 describes a 2009–2014 trial at 11 sites in seven African countries and pilot introduction beginning in Ghana, Kenya and Malawi in 2019. This geographical network mattered: research needed evidence from places with different malaria transmission conditions, while pilots investigated routine delivery rather than laboratory performance alone.

Vaccines prepare an immune response before exposure, reducing subsequent disease risk. RTS,S targets Plasmodium falciparum malaria and provides additional protection rather than removing the need for nets, diagnosis and treatment. It must not be described as the only malaria vaccine now available. WHO's February 2026 update covers both RTS,S and R21 and stresses comprehensive malaria control. A new tool changes the range of possible responses, but health systems and funding influence its practical reach.

GSK's HIV work also illustrates partnership rather than a single firm acting alone. Its majority-owned specialist company ViiV Healthcare develops antiretroviral medicines, which inhibit viral replication. GSK's January 2026 shareholding announcement confirms its continuing majority interest while describing changes involving Shionogi and Pfizer. Contributions by partner firms, researchers, public institutions and communities should not be credited solely to GSK. The geographical question is how this combined capacity affects both innovation and access.

Patents, manufacturing and global flows

A patent grants a time-limited legal right over an invention in the territories where it applies. It can help a firm recover risky research expenditure, but restrictions on competing production can also influence prices and access. A licence permits another producer to use specified intellectual property under agreed conditions. Neither a patent nor its absence determines access on its own: finance, regulation, quality assurance and the ability to manufacture remain important.

A concrete example is ViiV's licensing of dolutegravir, an HIV medicine, through the Medicines Patent Pool, or MPP. MPP negotiates licences that allow qualified manufacturers to supply generic versions within agreed territories. In April 2024, MPP reported that its agreements with ViiV, together with ViiV's direct agreements with Aurobindo Pharma, had enabled generic dolutegravir-based medicines to reach 24 million people in 128 low- and middle-income countries. This is an access outcome reported by the partnership at a stated date, not a claim that every patient everywhere received treatment.

Licensing changes the geography of supply by allowing additional manufacturers, including Indian generic firms, to serve eligible markets. Competition and larger volumes can improve affordability, while national procurement, clinics and continuing supplies determine whether medicines reach patients. Licence terms can exclude some territories or uses, and regulatory approval still matters. Therefore assess who is included, who remains underserved and whether supply is sustained, rather than assuming an agreement automatically creates universal access.

Vaccine technology transfer illustrates another distinction. In January 2021, GSK, PATH and Bharat Biotech announced a transfer agreement intended to support long-term RTS,S supply. Bharat Biotech in Hyderabad, India, would produce the vaccine antigen following transfer, while GSK would continue supplying the adjuvant, the component that strengthens the immune response. This describes an announced division of production, not a guarantee that every future milestone has been completed.

Technology transfer involves practical know-how, trained staff, equipment, validated processes and quality controls as well as legal permission. Donating finished doses provides a supply now but does not necessarily create local manufacturing capacity. Building capacity can diversify production and skills over time, yet requires investment and predictable demand. The GSK case therefore connects corporate power to a network of flows: knowledge and rights to manufacturers, finance through procurement, and products through international distribution to national services.

Worked argument scaffold — pharmaceutical power and disease control

Assess the relative importance of pharmaceutical TNCs in reducing the global disease burden. A developed argument weighs their capacity to innovate and organise production against the institutions that make those products accessible. These paragraphs resolve that comparison while providing a scaffold for a fuller extended answer.

Innovation and manufacturing power: GSK's RTS,S malaria work connects research finance with a geographical trial network. Trials in 2009–2014 operated at 11 sites in seven African countries; pilot introduction began in Ghana, Kenya and Malawi in 2019. The network matters because a product must work in populations exposed to the disease and be deliverable through routine services. TNC expertise and investment can therefore expand the set of biological tools available. However, attributing the breakthrough entirely to one company would overlook PATH, African researchers and public institutions. Its causal contribution is strongest as part of a research and production partnership, while the continued need for nets and care limits any claim that a vaccine alone controls malaria.

Access and institutions: patents give a firm influence over supply, but licensing can distribute that capacity. In April 2024 the Medicines Patent Pool reported that its ViiV agreements, together with ViiV's direct Aurobindo agreements, had enabled generic dolutegravir-based medicines to reach 24 million people in 128 low- and middle-income countries. This is more persuasive evidence of access than an announcement of research spending because it concerns patients reached. Its geographical boundaries remain important: the result does not establish universal treatment or cover every territory. Manufacturers require quality assurance, and national services still need procurement finance, trained staff and continuing supply. Legal permission opens a pathway; several actors convert it into usable care.

Resolved judgement: pharmaceutical TNCs are especially important where specialised research, regulation and complex manufacturing create high barriers to entry. Their importance in producing an intervention can exceed their power to ensure equitable outcomes. Governments, international partnerships and communities determine whether people can obtain and sustain treatment. Smallpox's eradication in 1980 demonstrates that disease reduction also depends on coordinated surveillance, delivery and inclusion. The strongest conclusion therefore concerns complementary functions: corporate capacity can be indispensable to particular innovations, while durable global control depends on a wider system capable of reaching the populations bearing the burden.